Marengo's invikafusp alfa shows responses across 8 tumor types in Phase 2 at ESMO
- Marengo Therapeutics reported Phase 2 results at ESMO 2026 for invikafusp alfa, described as a first-in-class dual T cell agonist.
- Objective responses were seen across eight tumor types.
- Responses were noted particularly in patients whose cancers had not responded to earlier checkpoint inhibitor therapy.
💡 Points
Eight tumor types responding is a breadth signal, but without response rates, sample sizes or durability, it reads as a platform teaser, not a registrational case. The sharper hook is activity after checkpoint failure, where unmet need is large and a T cell agonist can differentiate from PD-1 combinations. Expect Marengo to need a partner or financing, and to narrow to one or two lead indications.
ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2 ↗